Tevogen Bio Holdings Inc. (TVGN)

NASDAQ: TVGN · Real-Time Price · USD

0.6739

-0.1055 (-13.54%)

At close: Oct 3, 2025, 4:00 PM EDT

0.6760

+0.0021 (0.31%)

After-hours: Oct 3, 2025, 7:47 PM EDT

Tevogen Bio Holdings Employees

Tevogen Bio Holdings had 18 employees as of December 31, 2024.

Employees

18

Change

n/a

Growth

n/a

Revenue / Employee

n/a

Profits / Employee

-$1,747,994

Market Cap

132.56M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	18	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

TVGN News

10 days ago - Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion - GlobeNewsWire
12 days ago - Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID - GlobeNewsWire
16 days ago - Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489's Potential Impact for 20 Million Americans - GlobeNewsWire
25 days ago - Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston - GlobeNewsWire
26 days ago - Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection - GlobeNewsWire
27 days ago - Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform - GlobeNewsWire
4 weeks ago - Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas - GlobeNewsWire
4 weeks ago - Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2 - GlobeNewsWire